The Committee for Proprietary Medicinal Products adopted its Opinion at its meeting of 7-8 June 1995, saying that marketing authorisations for Naftidrofuryl should be withdrawn (Opinion and assessment report CPMP/ 345/ 95 appended to this Opinion).